Concert Pharmaceuticals, INC.: management transactions · United States · SEC (Form 4)

About Concert Pharmaceuticals, INC.

Concert Pharmaceuticals, Inc. was a U.S.-based biopharmaceutical company formerly listed on the NASDAQ under the ticker CNCE before being acquired by Sun Pharmaceutical in 2023. Headquartered in Lexington, Massachusetts, United States, the company was incorporated in 2006 and built its strategy around deuterium chemistry, a drug-discovery approach designed to improve the pharmacokinetic and metabolic properties of small-molecule therapeutics. As a result, Concert operated as a development-stage biotech with value creation tightly linked to clinical data, regulatory execution, intellectual-property protection, and access to capital. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1367920/000136792022000018/R8.htm?utm_source=openai)) Concert’s core business centered on its proprietary deuterated chemical entity platform, which it used to design and advance differentiated drug candidates. Its lead program was deuruxolitinib, formerly known as CTP-543, an oral JAK1/JAK2 inhibitor being developed for moderate-to-severe alopecia areata, an autoimmune dermatology condition that can cause significant hair loss and major quality-of-life impairment. The company advanced this asset through a pivotal Phase 3 program, THRIVE-AA, and long-term extension studies in North America and Europe. In 2022, Concert reported positive topline results from THRIVE-AA1 and THRIVE-AA2, with those data intended to support an FDA filing. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1367920/000136792022000018/cnce-20211231.htm?utm_source=openai)) From a competitive standpoint, Concert was positioned as an innovative but relatively small-cap biotech in a crowded and highly competitive therapeutic landscape. Its key differentiator was its deuterated-chemistry patent estate and its focus on improving established mechanisms through molecular design. That said, the company remained highly concentrated around a narrow pipeline, leaving it exposed to binary clinical and regulatory outcomes. In alopecia areata, it competed against larger pharmaceutical players and other specialty dermatology assets pursuing the same high-unmet-need market. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1367920/000136792022000018/R8.htm?utm_source=openai)) Recent milestones were dominated by the Phase 3 readouts in 2022 and the subsequent sale process. In January 2023, Concert announced a definitive agreement under which Sun Pharma would acquire all outstanding shares for $8.00 per share in cash, plus one contingent value right per share with potential additional payments of up to $3.50 tied to certain net-sales milestones. The transaction closed on March 6, 2023. For investors, that means CNCE is no longer an active listed equity, but its historical SEC filings, including Form 4 insider-transaction disclosures, remain relevant for event analysis and corporate-history review. ([sunpharma.com](https://sunpharma.com/wp-content/uploads/2023/01/Press-Release-Sun-Pharma-to-Acquire-Concert-Pharmaceuticals-Advancing-the-Potential-Treatment-of-Alopecia-Areata.pdf?utm_source=openai))